Objective: the application of losartan CanQi joint on centralizer diabetic rats model, the intervention of blood glucose, blood fat, renal function, albuminuria, plasma AngII level, kidney pathological changes and kidney tissues beta receptors and TGF - FNmRNA expression, this paper discusses the influence of the two drugs in diabetic rats renal protection exists synergy effect. Methods: 55 Wistar rats, which only 47 fasting 12-16 hours, free water/kg of 50mg, one-time dose intraperitoneal injection of 2% (urea chain with bacteria STZ streptozotocin 72h), angular measuring blood after fasting glucose mmol/L experiment.it 16.7 for diabetic rats, into the experiment, the no winners. Eight others as normal rats, injection of citric acid buffer is volume. Diabetic rats were randomly divided into three groups: model group, CanQi centralizer liquid, losartan and joint group (losartan and CanQi centralizer combination therapy group). Liquid Diabetes Mellitus (DM) and Diabetes after the establishment of the model, and begin treatment by rats and equivalent conversion dose lavage gives every timing method of losartan 10 mg/kg/d and CanQi centralizer injection 200mg/kg/d, joint lavage groups of 10 mg/kg/d / + 200mg/kg/d group, and group given equal 0.9% NS model. Article 8 weeks, when executed rats blood glucose, blood fat, kidney observation, albuminuria, kidney pathological changes, plasma levels, renal tissue Ang II TGF beta receptors and FNmRNA expression -. Results: compared with the normal group, and each drug model of rats blood glucose, blood group, renal function, urinary protein, plasma AngII significantly (P < 0.05) or P < 0.01), Glomerular basement membrane average area, capillary average thickness were significantly expand (P < 0.05). Renal tissues beta receptors and FNmRNA TGF - express significant increase (P < 0.05). Losartan, CanQi centralizer after intervention, CanQi centralizer liquid fluid can reduce high blood glucose (P < 0.01), increase HDL levels, reduce CHO, TG level (P < 0.05 or P < 0.01), but losartan to high status, lipid metabolism disorders affect (P > 0.05) is, CanQi lifter in liquid, kidney kidney hypertrophy, t. t. beta RI RII beta FNmRNA and expressed in the role than losartan (P < 0.05). Losartan Ang lower level II CanQi than lifter fluid (P < 0.05). Combined treatment group can further reduce urine protein, renal glomerulus index, the average area hypertrophy, alleviate these GBM thickening (P < 0.05). Conclusion: 1. To reduce blood sugar CanQi centralizer and lipids, improve renal function, reduce albuminuria, Ang II levels, kidney, T T beta RI RII beta FNmRNA and express. 2. Of hyperglycemia valerian, hyperlipidemia no obvious effect, but also can improve the general situation and kidney function, reduce albuminuria, Ang II levels. 3 CanQi centralizer and losartan synergistic effects: CanQi centralizer in liquid, kidney T kidney hypertrophy, RI beta RII beta FNmRNA and expressed in the role than losartan, Losartan Ang lower level II CanQi centralizer than liquid, Combined treatment group can further reduce urine protein, renal glomerulus index, the average area hypertrophy, alleviate these GBM thickening.
Keywords: diabetic nephropathy losartan CanQi centralizer liquid transfer growth factor beta system (T beta RI, T beta RII) and fibronectin (12.7mm FN) Ang II combination therapy
内容全部来源于网络收集，如有侵权，请联系网站删除！